<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
{mso-style-priority:1;
margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link="#0563C1" vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>See below for a number of articles.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>The list was provided by Walter Eadie of PCCN Oakville-Mississauga.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Of note is the 1 on genetic testing.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US>From:</span></b><span lang=EN-US> walter.eadie@cogeco.ca <br><br><o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US>Just FYI. As sent out to my own group.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'>Here is a summary of the interesting papers and articles I have read recently<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:black;border:none windowtext 1.0pt;padding:0cm;background:white'>Adding four months of </span></i><i><span lang=EN-US style='font-family:"Verdana",sans-serif'><a href="https://prostatecancernewstoday.com/hormone-therapy-and-prostate-cancer/"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white;text-decoration:none'>androgen deprivation therapy</span></a><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white'> (ADT) to </span><a href="https://prostatecancernewstoday.com/radiation-therapy/"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white;text-decoration:none'>radiation</span></a><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white'> treatment extends survival and delays metastasis in men with unfavorable intermediate-risk </span><a href="https://prostatecancernewstoday.com/prostate-cancer-overview/"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white;text-decoration:none'>prostate cancer</span></a><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white'>, according to a secondary analysis of a Phase 3 clinical trial.</span><span style='color:black;background:white'> <span style='border:none windowtext 1.0pt;padding:0cm'>However, that new trial analysis showed there were no such benefits to ADT therapy for men with favorable intermediate-risk prostate cancer undergoing radiation therapy.</span> <span style='border:none windowtext 1.0pt;padding:0cm'>These findings support the </span></span><a href="https://www.nccn.org/"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white;text-decoration:none'>National Comprehensive Cancer Network</span></a><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white'> recommendations that ADT treatment only be given to patients with unfavorable intermediate-risk prostate cancer.</span><span style='border:none windowtext 1.0pt;padding:0cm;background:white'><o:p></o:p></span></span></i></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:black;background:white'><a href="https://www.medpagetoday.com/hematologyoncology/prostatecancer/88518">https://www.medpagetoday.com/hematologyoncology/prostatecancer/88518</a> </span><span lang=EN-US style='font-family:"Verdana",sans-serif;background:white'><o:p></o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;background:white'><o:p> </o:p></span></i></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:black;background:white'>A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade </span></i><i><span lang=EN-US style='font-family:"Verdana",sans-serif'><a href="https://prostatecancernewstoday.com/prostate-cancer-overview/"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;background:white;text-decoration:none'>prostate cancer</span></a><span style='color:black;background:white'>, using slide images from patient core needle prostate biopsies, a study reports. </span><span style='color:#212121;background:white'>An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology.</span></span></i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#212121;background:white'> <a href="https://pubmed.ncbi.nlm.nih.gov/31926806/">https://pubmed.ncbi.nlm.nih.gov/31926806/</a><o:p></o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;background:white'><o:p> </o:p></span></i></p><p class=MsoNoSpacing><i><span lang=EN-US style='font-family:"Verdana",sans-serif'>“This is going to change everything.” Soon, you will find out your lifetime risk of getting prostate cancer through a simple saliva or blood test.<o:p></o:p></span></i></p><p class=MsoNoSpacing><i><span lang=EN-US style='font-family:"Verdana",sans-serif'>New Genetic Test Could Be the Ultimate In Early Detection<o:p></o:p></span></i></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:black;border:none windowtext 1.0pt;padding:0cm;background:white'><a href="https://www.pcf.org/c/new-genetic-test-could-be-the-ultimate-in-early-detection/?utm_source=NewsPulse&utm_medium=email&utm_campaign=OCT20NP">https://www.pcf.org/c/new-genetic-test-could-be-the-ultimate-in-early-detection/?utm_source=NewsPulse&utm_medium=email&utm_campaign=OCT20NP</a></span></i><i><span lang=EN-US style='font-family:"Verdana",sans-serif;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p></o:p></span></i></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p> </o:p></span></i></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'>“<i>The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of their cancer</i></span><span lang=EN-US style='font-size:10.5pt;font-family:"Times New Roman",serif;color:#333333;background:#F7F7F7'>.”<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'><a href="https://ascopost.com/news/october-2020/fluciclovine-pet-imaging-vs-conventional-imaging-in-prostate-cancer/?bc_md5=ce6d480b891e3ade6a267c9f9bc5f3fa&utm_source=TAP-EN-102720&utm_medium=email&fbclid=IwAR1etpN4_hj_QzdyLK0DAnbYasn3oHaj921H3UKzPscDTGKG6JAME0FMHWg">https://ascopost.com/news/october-2020/fluciclovine-pet-imaging-vs-conventional-imaging-in-prostate-cancer/?bc_md5=ce6d480b891e3ade6a267c9f9bc5f3fa&utm_source=TAP-EN-102720&utm_medium=email&fbclid=IwAR1etpN4_hj_QzdyLK0DAnbYasn3oHaj921H3UKzPscDTGKG6JAME0FMHWg</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.5pt;font-family:"Times New Roman",serif;color:#333333;background:#F7F7F7'><br></span><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'>Note, fluciclovine (brand name Axumin) is FDA approved for use in PC. PSMA/PET, which is claimed to be even better, is not yet approved but that is expected within months.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'>Expanding on the above - here is a recording of the best review of PSMA/PET imaging that I have seen – how and when it can be used and how it can change the treatment plan for a patient<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'><a href="https://www.gotostage.com/channel/586ae7e307c64183ad184b75a06a255c/recording/c8bb2ed2fd3a4d1bb075882755b9d84b/watch?source=CHANNEL">https://www.gotostage.com/channel/586ae7e307c64183ad184b75a06a255c/recording/c8bb2ed2fd3a4d1bb075882755b9d84b/watch?source=CHANNEL</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'>Here is something coming up on the same topic<o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333;background:#F7F7F7'>Pr</span><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333'>ostate Cancer Connections, <i>Imaging and Prostate Cancer Webinar</i><o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333'>Tuesday, November 24, 2020 7:00-8:30pm Central<o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333'>Register at: </span></i><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001SUkltLHGj1zM1_djSCr0k282Mn0V0zPz5e9eOnm-9olL375dPlIt7qeN9OaMSJYDtrQlTmgA7klToeusmeJQXnN2qGUn8IKgyKDg5t5tH6gxsSWMcn-AXCR0UE4TPuq9awxK_M1J944bsI8nzoZeAjogeOUnQd3U&c=oOEJuJU9gsGVvFYD1VKKUIjyE8cIRa880_ThmmhatYeg5eRO7pKS5w==&ch=bIRt4co0nI5sivdgQEkn7WE1EPP_Co2otpF0U7izkBcLLYhB7Qp0Ow==" target="_blank"><span style='color:#0078C1'>www.ustoo.org/connections</span></a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana",sans-serif;border:none windowtext 1.0pt;padding:0cm;background:white'><o:p> </o:p></span></i></p></div></body></html>